+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


EXFORGE HCT Drug Profile, 2019

  • ID: 4727090
  • Report
  • February 2020
  • Region: Global
  • 43 pages
  • thinkBiotech LLC
1 of 4


EXFORGE HCT Drug Profile, 2019 is part of a deep library of business intelligence on biopharmaceutical drugs.

The report focuses on EXFORGE HCT and covers the following critical aspects of this drug:
  • United States patents
  • Expired United States patents
  • FDA Paragraph IV patent challenges
  • District Court patent litigation
  • European supplementatry protection certificates (SPCs)
  • Clinical trials
  • Drug prices
  • Finished product suppliers
About the Researcher

The researcher is a provider of global business intelligence on biologic and small-molecule drugs, dedicated to helping clients make better decisions. Critical information on global drug patents is incorporated with litigation intelligence, drug prices, and historic sales figures to help users discover commercial opportunities and forecast future revenue events. Since 2005 the researcher has served hundreds of large and small companies in more than 65 countries.
Note: Product cover images may vary from those shown
2 of 4


  • Profile for EXFORGE HCT
  • US Patents
  • Expired US Patents
  • Paragraph IV Patent Challenges
  • US District Court Litigation
  • International (ex US) Patents
  • Supplementary Protection Certificates
  • Clinical Trials
  • Drug Prices - Average Pharmacy Cost
  • Finished Product Suppliers
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Novartis Pharmaceuticals Corporation
  • Sandoz Inc
Note: Product cover images may vary from those shown